Drugs / mRNA-3705
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05295433 | Mar 2022 → Apr 2034 expected | methylmalonic acidemia | ModernaTX, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04899310 | Aug 2021 → Apr 2026 | methylmalonic acidemia | ModernaTX, Inc. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2024-09-12 | ModernaTX, Inc. | Results Moderna R&D Day Highlights Progress and Strategic Priorities q4web.com ↗
Early results suggest potential decreases in annualized rates of MMA-related hospitalizations and MDEs compared to pre-treatment rates. |
| 2024-06-06 | ModernaTX, Inc. | Regulatory Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program q4web.com ↗
Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has selected mRNA-3705 for the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. |
| 2023-09-13 | ModernaTX, Inc. | Results Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease q4web.com ↗
With positive clinical data announced in mRNA-3705, a treatment for methylmalonic acidemia, the Company has three chronic rare disease medicines that have demonstrated potential for clinical benefit in patients |
| 2021-09-09 | ModernaTX, Inc. | Regulatory Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day q4web.com ↗
Moderna received rare pediatric designation for mRNA-3705. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-09-12 | ModernaTX, Inc. | Moderna R&D Day Highlights Progress and Strategic Priorities q4web.com ↗ |
| 2024-06-06 | ModernaTX, Inc. | Moderna's Investigational Therapeutic for Methylmalonic Acidemia (mRNA-3705) Selected by U.S. Food & Drug Administration for START Pilot Program q4web.com ↗ |
| 2023-09-13 | ModernaTX, Inc. | Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease q4web.com ↗ |
| 2021-09-09 | ModernaTX, Inc. | Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day q4web.com ↗ |
| 2021-08-16 | ModernaTX, Inc. | Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia q4web.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-3705 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05295433 ↗ |
| Modality | Messenger RNA (mRNA) | “modified mRNA encoding human” NCT04899310 ↗ |
| Route | Intravenous | “administered via intravenous infusion” NCT04899310 ↗ |